Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.17 USD
-1.91 (-2.61%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $71.20 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AXSM 71.17 -1.91(-2.61%)
Will AXSM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXSM
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Other News for AXSM
Neurocrine Biosciences upgraded at Wells Fargo on pipeline
Strong Buy on Axsome’s Auvelity Amidst Competitive MDD Market
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Auvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeutics
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting